Chardan Capital Maintains Buy Rating on Arrowhead Pharma, Sets $115 Target
Chardan Capital maintained its Buy rating and $115 price target for Arrowhead Pharmaceuticals. The target implies 97.0% upside from the Oct. 14 close of $58.37.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.